A commonly prescribed anti-nausea drug, aprepitant, may offer more than just relief from chemotherapy-induced discomfort. According to a new observational study, this medication could significantly improve survival outcomes for women battling aggressive forms of breast cancer. The research, conducted by Monash University in collaboration with the Norwegian Institute of Public Health, found that aprepitant use during chemotherapy was associated with a reduced risk of cancer metastasis and breast cancer-related death—particularly in patients with triple-negative breast cancer (TNBC), one of the most challenging subtypes to treat.

Anti-nausea medications are a routine part of cancer treatment, helping patients manage the often debilitating side effects of chemotherapy. Aprepitant, part of a class of drugs known as neurokinin 1 receptor (NK1R) antagonists, works by blocking the action of substance P, a neuropeptide involved in triggering nausea and vomiting. While its role in easing side effects is well established, researchers were intrigued by earlier findings that linked the substance P pathway to cancer progression. This connection prompted a deeper look into whether aprepitant could influence long-term cancer outcomes.

The study analyzed data from 13,811 women in Norway who were diagnosed with invasive early-stage breast cancer between 2008 and 2020. All participants had undergone chemotherapy and received anti-nausea medications. Researchers focused on two key metrics: distant disease-free survival (DDFS), which measures time until cancer spreads or the patient dies, and breast cancer-specific survival (BCSS), the time until death from the disease itself. Women who filled at least one prescription for aprepitant within a year of diagnosis were considered users.

After adjusting for variables such as age, cancer stage and subtype, chemotherapy type, and use of other anti-nausea drugs like ondansetron and dexamethasone, the findings showed a meaningful survival benefit. Overall, aprepitant users had an 11% lower risk of metastasis or death and a 17% lower risk of dying from breast cancer. The benefits were even more pronounced in women with aggressive subtypes. For those with TNBC, aprepitant use was linked to a 34% reduction in metastasis risk and a striking 39% decrease in breast cancer-specific mortality.

I found this detail striking: a medication originally designed to manage side effects may be contributing to improved survival, especially in high-risk groups. TNBC, which lacks estrogen, progesterone, and HER2 receptors, does not respond to many of the targeted therapies available for other breast cancer types. Its aggressive nature and limited treatment options make any potential advancement particularly meaningful.

HER2-positive breast cancers, which overexpress a protein that accelerates cell growth, also showed some benefit from aprepitant use. However, the study did not find a statistically significant survival advantage in hormone-receptor-positive (luminal) breast cancers, which typically have a better prognosis and more treatment options.

Another notable finding was the observed dose-response trend. Longer use of aprepitant appeared to correlate with better outcomes. Women who used the drug for 12 days saw up to a 42% reduction in the risk of recurrence or death. Typically, aprepitant is administered during the first three days of chemotherapy. This raises the question of whether extending its use could yield even greater benefits. Dr. Aeson Chang of the Monash Institute of Pharmaceutical Sciences noted that this possibility warrants further investigation.

Despite the promising results, the study has several limitations. Because it was observational and not a randomized controlled trial, it cannot establish a definitive cause-and-effect relationship. Aprepitant users were more likely to receive more intensive chemotherapy, which could influence outcomes despite statistical adjustments. There is also no guarantee that patients who filled prescriptions actually took the medication. Additionally, survival tracking began one year after diagnosis, potentially excluding early deaths and skewing results. Some non-users may have taken similar NK1R antagonists, possibly diluting the observed effect.

Even with these caveats, the findings open new avenues for research and potential treatment strategies. If future randomized trials confirm these results, aprepitant could be repurposed as more than just a supportive care drug. It might become part of a broader cancer therapy regimen, particularly for patients with aggressive breast cancer subtypes who currently have limited options.

Dr. Edoardo Botteri, the study’s lead author and a pharmacoepidemiologist at the Cancer Registry of Norway, emphasized the need for further research. “Given what this study has uncovered, it’s essential these links are further explored—we now need to better understand why these associations have presented themselves, and from there we can look at what this might mean for prescribing and dosing regimens in the future,” he said.

This research not only highlights the potential of aprepitant as a co-treatment in oncology but also underscores the importance of investigating the broader biological effects of medications already in clinical use. As we continue to seek more effective ways to treat aggressive cancers like TNBC, studies like this offer a hopeful glimpse into how existing therapies might be leveraged in new, life-extending ways.

Read more at newatlas.com